171 related articles for article (PubMed ID: 18682698)
1. Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice.
Chang AH; Stephan MT; Lisowski L; Sadelain M
Mol Ther; 2008 Oct; 16(10):1745-52. PubMed ID: 18682698
[TBL] [Abstract][Full Text] [Related]
2. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
[TBL] [Abstract][Full Text] [Related]
3. Efficient induction of immune tolerance to coagulation factor IX following direct intramuscular gene transfer.
Cohn EF; Zhuo J; Kelly ME; Chao HJ
J Thromb Haemost; 2007 Jun; 5(6):1227-36. PubMed ID: 17362228
[TBL] [Abstract][Full Text] [Related]
4. Stem cell-derived erythroid cells mediate long-term systemic protein delivery.
Chang AH; Stephan MT; Sadelain M
Nat Biotechnol; 2006 Aug; 24(8):1017-21. PubMed ID: 16845377
[TBL] [Abstract][Full Text] [Related]
5. Expression of human factor IX gene in murine plasma through lentiviral vector-infected haematopoietic stem cells.
Chen H; Yao H; Huang L; Shen Q; Jia W; Xue J
Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1196-201. PubMed ID: 17184501
[TBL] [Abstract][Full Text] [Related]
6. A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo.
Ehrhardt A; Kay MA
Blood; 2002 Jun; 99(11):3923-30. PubMed ID: 12010790
[TBL] [Abstract][Full Text] [Related]
7. Genetic modification of bone-marrow mesenchymal stem cells and hematopoietic cells with human coagulation factor IX-expressing plasmids.
Sam MR; Azadbakhsh AS; Farokhi F; Rezazadeh K; Sam S; Zomorodipour A; Haddad-Mashadrizeh A; Delirezh N; Mokarizadeh A
Biologicals; 2016 May; 44(3):170-7. PubMed ID: 26928674
[TBL] [Abstract][Full Text] [Related]
8. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
[TBL] [Abstract][Full Text] [Related]
9. [Preparation of rAAV2/hFIX and experimentally application to gene therapy for hemophilia B].
Peng JQ; Dong XY; Peng M; Chen L; Tan SP; Yuan H; Chen FP; Xue JL; Wu XB
Zhonghua Xue Ye Xue Za Zhi; 2004 Sep; 25(9):513-8. PubMed ID: 15569526
[TBL] [Abstract][Full Text] [Related]
10. Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
Levin D; Lagassé HA; Burch E; Strome S; Tan S; Jiang H; Sauna ZE; Golding B
J Thromb Haemost; 2017 Apr; 15(4):721-734. PubMed ID: 28166609
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells.
Persons DA; Allay ER; Sawai N; Hargrove PW; Brent TP; Hanawa H; Nienhuis AW; Sorrentino BP
Blood; 2003 Jul; 102(2):506-13. PubMed ID: 12663444
[TBL] [Abstract][Full Text] [Related]
12. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo.
Miao CH; Thompson AR; Loeb K; Ye X
Mol Ther; 2001 Jun; 3(6):947-57. PubMed ID: 11407909
[TBL] [Abstract][Full Text] [Related]
13. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
Zhang R; Wang Q; Zhang L; Chen S
Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
[TBL] [Abstract][Full Text] [Related]
14. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice.
Wen J; Xu N; Li A; Bourgeois J; Ofosu FA; Hortelano G
J Gene Med; 2007 Nov; 9(11):1002-10. PubMed ID: 17868187
[TBL] [Abstract][Full Text] [Related]
15. Complete and sustained phenotypic correction of hemophilia B in mice following hepatic gene transfer of a high-expressing human factor IX plasmid.
Ye X; Loeb KR; Stafford DW; Thompson AR; Miao CH
J Thromb Haemost; 2003 Jan; 1(1):103-11. PubMed ID: 12871546
[TBL] [Abstract][Full Text] [Related]
16. Implantation of autologous skin fibroblast genetically modified to secrete clotting factor IX partially corrects the hemorrhagic tendencies in two hemophilia B patients.
Qiu X; Lu D; Zhou J; Wang J; Yang J; Meng P; Hsueh JL
Chin Med J (Engl); 1996 Nov; 109(11):832-9. PubMed ID: 9275366
[TBL] [Abstract][Full Text] [Related]
17. In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy.
Chen Y; Schroeder JA; Gao C; Li J; Hu J; Shi Q
J Cell Physiol; 2021 Jan; 236(1):354-365. PubMed ID: 32510630
[TBL] [Abstract][Full Text] [Related]
18. Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy.
Grimm D; Zhou S; Nakai H; Thomas CE; Storm TA; Fuess S; Matsushita T; Allen J; Surosky R; Lochrie M; Meuse L; McClelland A; Colosi P; Kay MA
Blood; 2003 Oct; 102(7):2412-9. PubMed ID: 12791653
[TBL] [Abstract][Full Text] [Related]
19. Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.
Le Quellec S; Dane A; Enjolras N; McIntosh J; Rosales C; Negrier C; Nathwani A
Haemophilia; 2019 Jan; 25(1):e11-e18. PubMed ID: 30520547
[TBL] [Abstract][Full Text] [Related]
20. Efficient delivery of human clotting factor IX after injection of lentiviral vectors in utero.
Chen XG; Zhu HZ; Gong JL; Li F; Xue JL
Acta Pharmacol Sin; 2004 Jun; 25(6):789-93. PubMed ID: 15169633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
